Delhi is grappling with a severe smog crisis as toxic air quality persists, placing it in the 'very poor' and 'severe' categories. Doctors report a significant surge in pollution-related respiratory ...

Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...

Vermont has one of the highest rates of pediatric asthma in the country — one analysis found that in Vermont, 8.3% of people under the age of 17 have asthma, according to 2023-24 data from the U.S.

On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Kolkata: A surge in pneumonia and COPD patients has left several private hospitals close to full occupancy, leading to a ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...

FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.